Sumavel DosePro, Levadex to Earn About $400 Million in Combined Sales by 2018

Decision Resources … finds that Zogenix/Astellas Pharma/Desitin Pharmaceuticals’ needle-free Sumavel DosePro, which launched earlier this month in the United States, and MAP Pharmaceuticals’ orally-inhaled Levadex will earn approximately $400 million in combined sales by 2018 in the migraine drug market.
StreetInsider